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Spastic paraplegia 46 refers to a locus mapped to chromosome 9 that accounts for a complicated autosomal-recessive form of hereditary
spastic paraplegia (HSP).With next-generation sequencing in three independent families, we identified four differentmutations inGBA2
(three truncating variants and one missense variant), which were found to cosegregate with the disease and were absent in controls.
GBA2 encodes a microsomal nonlysosomal glucosylceramidase that catalyzes the conversion of glucosylceramide to free glucose and
ceramide and the hydrolysis of bile acid 3-O-glucosides. The missense variant was also found at the homozygous state in a simplex
subject in whom no residual glucocerebrosidase activity of GBA2 could be evidenced in blood cells, opening the way to a possible
measurement of this enzyme activity in clinical practice. The overall phenotype was a complex HSP with mental impairment, cataract,
and hypogonadism inmales associatedwith various degrees of corpus callosum and cerebellar atrophy on brain imaging. Antisensemor-
pholino oligonucleotides targeting the zebrafish GBA2 orthologous gene led to abnormal motor behavior and axonal shortening/
branching of motoneurons that were rescued by the human wild-type mRNA but not by applying the same mRNA containing the
missense mutation. This study highlights the role of ceramide metabolism in HSP pathology.Hereditary spastic paraplegias (HSPs) are heterogeneous
inherited neurodegenerative disorders. Affected individ-
uals suffer from pyramidal motor neuron dysfunction
such as spasticity, brisk reflexes, and pyramidal weakness
of the lower limbs primarily caused by dysfunction or
degeneration of upper motor neurons.1,2 These clinical
symptoms are sometimes associated with additional neu-
rological or extraneurological signs and structural abnor-
malities of the central nervous system (CNS) observed on
brain magnetic resonance imaging (MRI), such as thin
corpus callosum (TCC), cortical atrophy, and cerebellar
atrophy. This clinical heterogeneity partially reflects the
large genetic heterogeneity of this group of disorders
with ~50 loci mapped to date and accounting for all modes
of inheritance.3
We mapped SPG46 to chromosome 9 (MIM 614409) in
a consanguineous Tunisian family (TUN35) (Figure 1A)
with autosomal-recessive (AR) HSP, mental impairment,
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comparative genomic hybridization (NimbleGen chromo-
some 9-specific 385K array, data not shown). We then
sequenced all coding exons of the SPG46 candidate
interval (n ¼ 1,727 exons and their flanking splice sites
in 183 genes, including 1 kb of their UTRs) by targeted
next-generation sequencing (custom NimbleGen capture
and sequencing in a Roche 454-FLX) in affected subjects
V.32 and V.33 (Table S1 available online). After exclusion
of variants reported as validated polymorphisms in public
(1000 Genomes, dbSNP) and local databases, a total of 52
homozygous variants remained common to both individ-
uals, including 48 synonymous or intronic changes or
variants in pseudogenes. In the absence of nonsense or
intronic/exonic splice-site mutations, we focused our anal-
ysis on the four missense variants. Three of them cosegre-
gated with the disease, were predicted to be damaging by
various online software packages (PolyPhen-2, Muta-
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Figure 1. Mutations in GBA2
(A–D) Family trees and segregation analysis of the mutations iden-
tified in individuals of families TUN35 (A), Ng121 (B), F18310 (C),
and FSP824 (D). The following symbols are used: squares formales,
circles for females; filled symbols for affected individuals; gray
symbols for subjects not clinically assessed; double line for
consanguinity; m, mutation; þ, wild-type; *, sampled individuals.
Sequencing chromatograms of mutations c.518G>A (p.Trp173*),
c.700C>T (p.Arg234*), c.1888C>T (p.Arg630Trp), and c.1471_
1474dupGGCA (p.Thr492Argfs*9) are in Figure S1.
(E) Graphic representation of the exon organization of GBA2 on
chromosome 9 (gray boxes) and the location of the mutations
(black arrows). The GBA2 transcript is 3,611 bp long (CDS
2,784 bp) and is composed of 17 exons that encode a 927 amino
acid protein. White boxes show the exons encoding the glucosyl-
ceramidase domain.were excluded as the cause of the disease either because of
the frequency in controls (c.88C>T [p.Arg30Trp],
rs75679360, in FAM166B [RefSeq accession number
NM_001164310.1], found in 8/182 chromosomes of North
African controls, including at the homozygous state in
one subject) or because the corresponding gene hadThe Americpreviously been involved, when mutated, in another
autosomal-recessive disease not overlapping with HSP
(c.2909T>C [p.Val970Ala] in NPR2 [MIM 108961, RefSeq
NM_003995.3]). Indeed, we did not detect segregating
variants in NPR2 in 68 AR-HSP index subjects and 44
simplex individuals subjected to exome sequencing. The
remaining variant, c.1888C>T (p.Arg630Trp), found in
exon 12 of GBA2 (MIM 609471, RefSeq NM_020944.2),
segregated with the disease in the family (Figures 1A and
S1) and was detected neither in 1,038 control chromo-
somes of 519 French, West Indian, Brazilian, and North
African healthy subjects nor among 6,500 exomes on
the Exome Variant Server. The variant affected an amino
acid conserved from Caenorhabditis elegans and located
in the six-hairpin-glucosidase-like domain of the enzyme
(Figure 1E).
In parallel, exome capture via the SureSelect Human All
Exon 50Mb kit (Agilent) followed by sequencing on aHiseq
2000 sequencer (Illumina) was performed on the genomic
DNA of two index HSP individuals of Belgian and Turkish
ancestry, Ng121-II.2 and F18310-V.16484, respectively
(Figures 1B and 1C). The Burrows-Wheeler algorithm5
was used to align 100 bp length paired-end reads to the
hg19 version of the human genome (Ensembl); variants
were called with the Genome Analysis Toolkit (GATK)
software package.6,7 Data were then imported into the
Genomes Management Application (GEM-app) database
and its associated toolset for further analysis. On average,
110.4 million reads were produced per sample, 95%
of which could be aligned to the targeted sequence.
Mean coverage of the targeted sequence was 97-fold. On
average, 87,591 single-nucleotide variations (SNV) and
8,876 indels were called per sample. Variants were filtered
for occurrence in the normal population (minor allele
frequency < 1% in dbSNP135 and at the Exome Variant
Server), conservation (Genomic Evolutionary Rate Pro-
filing [GERP] score > 3.5 or PhastCons score > 0.7), and
quality (GATK QUAL score > 100, GATK GQ score > 75).
Variants occurring and segregating in more than two unre-
lated families in GEM-app were removed. Compound
heterozygous variants in eight genes, in the absence of
homozygous variants, were identified in the index subject
of family Ng121. In family F18310, 23 homozygous
changes and compound heterozygous variants in three
genes were identified in the sequenced subject. Among
all variants detected in both families, three were truncating
mutations and cosegregated with the disease (Figures 1B,
1C, and S1), all located in GBA2: c.700C>T (p.Arg234*)
at the homozygous state in exon 4 of individual F18310-
V.16484, and the heterozygous variants c.518G>A
(p.Trp173*) and c.1471_1474dupGGCA (p.Thr492Argfs*9)
in exons 3 and 9 of subject Ng121-II.2.
Direct Sanger sequencing (Table S2) of the 17 coding
exons of GBA2 in 95 index HSP subjects with an AR com-
patible inheritance (study approved by the Paris-Necker
ethics committee; approval No. 03-12-07 granted to A.B.
and A.D.), identified one simplex subject of Portuguesean Journal of Human Genetics 92, 238–244, February 7, 2013 239
Figure 2. Brain Imaging in SPG46-Affected Individuals
(A) Sagittal brain magnetic resonance imaging (MRI) in subject
FSP824-V.14 after 14 years of disease duration, showing a very
slight thinning of the corpus callosum (red arrow).
(B and C) Sagittal and transversal flair MRI of individual F18310-
V.16484 after 39 years of disease duration. The atrophy of the
corpus callosum (B, red arrow) and of the cerebellar (B, blue arrow)
and cerebral (B, white arrow) cortex are evident in the absence of
relevant white matter disease (C).
(D and E) Sagittal T1- and transversal axial T2-weighted MRI
images of subject Ng121-II.2 after 65 years of disease duration,
showing severe atrophy of her cerebellum (D, blue arrow) and
cerebrum (white arrows) with mesencephalon atrophy (D,
hummingbird/colibri sign, green arrow) and pronounced white
matter lesions (E, black arrowhead).ancestry (FSP824-V.14) harboring the samemissense muta-
tion (c.1888C>T [p.Arg630Trp]) as in family TUN35,
although with a different associated haplotype (Figures
1D and S1). The mutation, which was homozygous, was
detected at the heterozygous state in her parents.
The GBA2 protein encoded by GBA2 is an enzyme of
sphingolipid metabolism that is the source of a variety of
mediators of cell signaling responses and of structural
components of the plasma membrane involved in its
dynamics.8 GBA2 was initially identified as a microsomal
bile acid b-glucosidase or b-glucosidase 2,9,10 but it is also
a nonlysosomal glucosylceramidase, a ubiquitous enzyme
that catalyzes the conversion of glucosylceramide to
free glucose and ceramide as well as the reverse reaction
consisting in the transfer of glucose to different lipid
substrates.11,12 The primary catabolic pathway for gluco-
sylceramide involves the lysosomal enzyme glucocerebro-
sidase GBA1 (MIM 606463), which is defective in persons
with Gaucher disease, the most common inherited lyso-
somal storage disorder.13 GBA1 is located in the lysosomal
compartment and ceramides generated by this enzyme are
degraded into sphingosine and fatty acids.11,14 In contrast,
GBA2 has been localized in the endoplasmic reticulum
(ER)12 and at the cell surface,11 and ceramides formed
by this enzyme are rapidly converted into sphingomye-
lin.11,12,15 With a published protocol,16,17 we assessed the
GBA2 glucosylceramidase enzymatic activity in lympho-
blasts and leukocytes of affected persons harboring the
missense c.1888C>T (p.Arg630Trp) mutation in presence
of specific inhibitors of the GBA1 enzyme, which is respon-
sible for the vast majority of the glucosylceramidase
activity.18 No detectable GBA2 activity could be observed
in the cells of subject FSP824-V.14 compared to healthy
controls (p ¼ 0.001, Figure S2), indicating a complete loss
of function by the mutation. Complete loss of function
was also evidenced in nontransformed leukocytes of indi-
viduals TUN35-V.27 and V.33 (data not shown).
The neurological phenotype of the 11 affected individ-
uals was similar (Table S3). Onset occurred in infancy or
childhood (range 1–16 years) with disturbances that pro-
gressed slowly to the need for a cane at 22–32 years and
the need for a wheelchair at the age of 54–60. During the
course of the disease, cerebellar ataxia and cataract were
observed in all individuals. All affected subjects also had
mild tomoderate mental impairment; two explored during
their 50s showed an IQ level equivalent to that of 6-year-
old. In the oldest affected subjects, disease course was
complicated by a memory deficit in their 60s and they
died in a demented state aged 61, 63, and 72 years. The
initial phenotypic description4 was enriched by other
frequently observed signs, such as hearing loss (n ¼ 3)
and axonal neuropathy evidenced at electroneuromyogra-
phy (ENMG, n ¼ 5) and sural nerve biopsy (n ¼ 3). Brain
MRI showed cerebral, cerebellar, and corpus callosum
atrophy in all seven subjects tested, which seemed to
worsen with disease duration (Figure 2). Interestingly, the
two affected men presented a bilateral testicular hypotro-240 The American Journal of Human Genetics 92, 238–244, Februaryphy in the absence of hormonal dysfunctions. Semen
analysis of subject TUN35-V.27 revealed extremely severe
spermatozoid head abnormalities with necrospermia and
severe reduction in velocity (Table S4). Hormonal and
genital exploration of affected woman FSP824-V.14 did
not reveal abnormalities but woman Ng121-II.2 was re-
ported to have few pubic hairs. The infertility highlighted
in SPG46 males is reminiscent of the consequences of
the pharmacological inhibition of glucosylceramidases in
mice19,20 or observed in the Gba2 knockout (KO) mice
in which an abnormal glucosylceramide accumulation in
Sertoli cells is observed.12 This infertility together with
the neurological symptoms in our SPG46 subjects points
to the critical role of this enzyme in multiple tissues,
including testis and brain. Indeed, even if no overt neuro-
logical signs, liver dysfunction, or reduced viability were
observed in the Gba2 KO mice at 4 months of age, an7, 2013
Figure 3. zGba2 Inactivation Induces Morphological Phenotypes and Abnormal Motoneuronal Outgrowth in Zebrafish Larvae
(A–D)Whereas 48 hpf embryos injected with 0.1 pmol of the control AMOmmzGba2aug (B) were phenotypically indistinguishable from
noninjected controls (A), injection of 0.1 pmol zGba2aug (D) impaired embryonic development of the caudal region, with some mor-
phants showing shortened and/or twisted tails. Most of the injected morphants were normal looking even when they showed abnormal
locomotion (C). Magnification 344.
(E) Classification of morphant phenotypes observed after injection of AMOs with or without mRNA. The numbers of noninjected
controls and different zGba2 morphants are indicated in parentheses. *p < 0.002, **p < 0.001.
(F–I) Noninjected and zGba2 morphants were analyzed for Znp-1 staining in spinal neurons. In contrast to noninjected larvae and to
morphants injected with mmzGba2 (F) or zGba2aug þ hGBA2 WT mRNA (H), morphants injected with the zGba2aug AMO in presence
(I) or absence (G) of the mutated c.1888C>T RNA showed dramatically impaired axonal outgrowth leading to truncated axons (arrow-
heads). Axon trajectories are disturbed; ectopic and aberrant motor axon branches can be seen (arrows). Scale bar represents 50 mm.accumulation of glycolipid species in the brain, liver, and
testis was observed by mass spectrometry.12 Longer times
may be required in mouse as shown in other HSP mouse
models in which signs are very subtle during the first
months of life.21,22 The neurological phenotype may also
be obscured by the different structure of corticospinal
tracts in mice or by compensation by other GBA enzymes
early during development. Such compensation in GBA1
mutated individuals by GBA2 activity has been shown
and may explain the absence of notable glucosylceramide
accumulation in some Gaucher disease subjects.17 The
reverse situation was not true because, in our study, no
difference in GBA1 activity could be observed between
lymphoblasts of the Portuguese subject and five controls
(data not shown). This compensation may, however, differ
between tissues and between different species.20
To validate the functional phenotype of the GBA2
mutations in vivo, and in particular in the CNS, we usedThe Americthe zebrafish model and antisense morpholino oligonucle-
otide (AMO) technology to knock down the unique GBA2
ortholog (zGba2; RefSeq NM_ENSDARG00000061472)
by using classical methodologies.23 To inactivate zGba2,
we used an AMO targeting the initiation codon of the
mRNA (zGba2aug). As a control for our results, we designed
a mismatch zGba2aug AMO, mmzGba2aug, comprising five
mismatched bases, whose injection did not significantly
lead to the appearance of phenotypes in injected embryos
compared to uninjected ones (p > 0.05). We determined
that microinjection of 0.1 pmol of zGba2aug did not cause
significant lethality of injected embryos compared to un-
injected (p > 0.05) or mmzGba2aug-injected (p > 0.05)
embryos. This AMO dose induced a curly tail phenotype
in 12.5% of morphants (Figures 3D and 3E) although
73.8% had no visible phenotype (Figure 3C). To further
characterize the phenotype of normal-looking embryos
(Figure 3C), we assessed their motor behavior byan Journal of Human Genetics 92, 238–244, February 7, 2013 241
performing a touch-response test on 2 day postfertilization
morphants (Figure S3). We clearly observed that a substan-
tial proportion of the normal-looking zGba2aug-injected
morphants showed significant motility defects (24%),
characterized by slower movements and shorter touch-
induced escape distances, when compared to control
embryos injected with mmzGba2aug (5.6%, p < 0.001)
(Figure 3E). We next investigated the conservation of the
GBA2 protein functions between human and zebrafish
by coinjecting zGba2aug with the wild-type (WT) human
GBA2 mRNA. When double injected, the number of
normal-looking morphants with no locomotor impair-
ment increased significantly (68.4% versus 49.8%)
compared to zGba2aug-injected larvae (Figure 3E, p <
0.001), suggesting that, in zebrafish, human GBA2 mRNA
can compensate, at least partially, for the loss of endoge-
nous zebrafish mRNA. Indeed, the orthologous genes
have a 65.8% identity and an 86.5% similarity. In contrast,
no significant difference (p > 0.05) was observed after the
coinjection of the zGba2aug AMO with the human GBA2
mRNA containing the c.1888C>T missense mutation
(Figures 3E and 3S), meaning that the mutated mRNA
failed to compensate the zebrafish mRNA decrease. Injec-
tion of WT or mutant mRNA alone, without morpholinos,
did not lead to a curly-tail or a locomotor phenotype and
did not influence lethality in embryos compared to
mmzGba2aug-injected control embryos (p > 0.05). Histo-
chemical analyses were then performed on zGba2aug-in-
jected morphant embryos showing a motor phenotype
without visible anomalies. The Znp-1 antibody, which
labels the synaptic protein synaptotagmin 2 in motor
neuron axons,24 showed abnormal development of the
spinal motoneurons, observed at mid-distance between
head and tail (Figure 3G). We observed and evaluated the
morphology of motor neuron axons in embryos injected
with zGba2aug, which appeared to be shorter and presented
with more terminal branches in contrast to the proper
axonal outgrowth observed in embryos injected with
the mmzGba2aug control (Table S5, p < 0.00001). This
abnormal outgrowth was totally rescued when zGba2aug
was coinjected with the WT human mRNA (Figure 3H
and Table S5, p ¼ 0.87), supporting the specificity of
our model. In contrast, we did not observe any rescue
when the coinjection was performed with the mutated
human c.1888C>T mRNA (Figure 3I and Table S5, p <
0.00001). These observations suggest that, in SPG46, as
in other HSPs,23,25–29 the neuronal tract formation is
defective and they confirm the role of GBA2 in the CNS
development.
Could treatments in use for Gaucher disease, due to
GBA1 mutations, be useful in GBA2 mutated individuals?
Enzyme replacement with imiglucerase (Cerezyme, Gen-
zyme; Velaglucerase alpha, Shire; etc.) will not be effective
because it does not cross the blood-brain barrier and has
been optimized to target lysosomes, which is not the local-
ization of GBA2. Another therapy, called substrate reduc-
tion therapy, uses the iminosugar-based inhibitor N-butyl-242 The American Journal of Human Genetics 92, 238–244, Februarydeoxynojirimycin (miglustat or Zarvesta, Actelion) or a
structural analog (Gen 529448, Genzyme) that decrease
glucosylceramide biosynthesis in vitro and have been re-
ported to increase survival and motor functions of mice
models of Niemann Pick type C1 (MIM 257220) and
Sandhoff (MIM 268800) diseases.20,30–32 However, these
inhibitors also acted on GBA2 enzymatic activity,32
making them unsuitable for SPG46 subjects. Moreover,
a pharmacological chaperone strategy, such as isofago-
mine used in Gaucher disease, may be an interesting
therapeutic option in SPG46 subjects due to missense
mutations, if adapted to the GBA2 protein, because it
was shown to increase GBA1 activity in GBA1 mutant
fibroblasts, reduce glucosylceramide and glucosylsphingo-
sine accumulations in mouse models, and improve neuro-
logical symptoms in subjects with type III Gaucher disease
(MIM 231000).33,34
In conclusion, we have identified mutations in GBA2
leading to a specific phenotype that connects glucosylcer-
amidemetabolism and HSP. Lipid metabolism defects have
already been implicated in other forms of HSP,35 including
SPG35 (MIM 612319), SPG28 (MIM 609340), or SPG49
caused by mutations in FA2H (MIM 611026), DDHD1
(MIM 614603), and CYP2U1 (MIM 610670), respec-
tively.36,37 Interestingly, measurement of specific activities
of enzymes involved in HSP could be useful to facilitate
diagnosis in clinical practice and to monitor drug response
in future therapeutic trials, even when done in the periph-
eral blood cells as in SPG5A (MIM 270800)38 or in SPG46
subjects in our study. Measurement of GBA1 activity is
already in use in Gaucher disease assessment.Supplemental Data
Supplemental Data include three figure and five tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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